Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Entera Bio (NASDAQ:ENTX) posted its quarterly earnings data on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01, Zacks reports. The business had revenue of $0.04 million during the quarter.

Entera Bio Stock Down 3.2 %

ENTX stock opened at $2.15 on Friday. The company has a market cap of $97.66 million, a price-to-earnings ratio of -8.27 and a beta of 1.51. Entera Bio has a twelve month low of $1.41 and a twelve month high of $2.79. The business has a 50 day moving average price of $1.92 and a two-hundred day moving average price of $2.03.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Entera Bio in a research note on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.